Highlights
A collection of news and information related to Benlysta (drug) published by this site and its partners.
Displaying items 1-5 of 5
» View latimes.com items only
-
Glaxo's fight for Human Genome Sciences gets nasty
British pharmaceutical giant GlaxoSmithKline is dropping the cordial overtures toward its takeover target and occasional business partner Human Genome Sciences Inc. Instead, Glaxo plans to launch a hostile $2.6-billion tender offer this week, putting its...
Tags: Drugs and Medicines, Rockville (Bethlehem, Pennsylvania), Diabetes, Lupus, Chemical Industry
-
GlaxoSmithKline to acquire Human Genome Sciences
After spurning a hostile takeover bid from GlaxoSmithKline PLC in April, Human Genome Sciences Inc. said Monday it agreed to be bought by the biopharmaceutical giant for a more lucrative offer valued at $3.6 billion.
GlaxoSmithKline boosted its offer for...Tags: Human Genome Sciences Inc., Rockville (Bethlehem, Pennsylvania), MedImmune Inc., Bristol Myers Squibb Company, Diabetes
-
Ripley's opens Odditorium at Harborplace
Ripley's Believe It or Not, one of the first of several new tenants opening for the summer tourist season at Harborplace in downtown Baltimore, will open Saturday in the Light Street Pavilion. Ripley Entertainment Inc. said exhibits at the Inner Harbor...Tags: Human Genome Sciences Inc., Rockville (Bethlehem, Pennsylvania), Justice System, Kevin J. Carey, Productivity
-
Consolidation wave poised to hit state's health care services, biopharma sectors
Like a one-two punch, two major Maryland employers in the health care service and pharmaceutical industries were the targets last week of multibillion-dollar acquisition deals. Both homegrown companies — Human Genome Sciences Inc. and Catalyst...Tags: Human Genome Sciences Inc., Rockville (Bethlehem, Pennsylvania), Stock Market, Restructuring and Recapitalization, MedImmune Inc.
-
Human Genome Sciences rebuffs $2.6 billion offer from GlaxoSmithKline
Shares of Human Genome Sciences doubled in Thursday morning trading on news that a major British biopharmaceutical company offered to buy it for $2.6 billion, which the Rockville company rejected as too low. Human Genome, which uses the human DNA...Tags: Human Genome Sciences Inc., Rockville (Bethlehem, Pennsylvania), Stock Market, Diabetes, GlaxoSmithKline PLC
May 9, 2012
|Story| Los Angeles Times
Jul 16, 2012
|Story| Baltimore Sun
Jun 8, 2012
|Story| Baltimore Sun
Apr 21, 2012
|Story| Baltimore Sun
Apr 19, 2012
|Story| Baltimore Sun
